Protocols

Israel’s Teva puts foreigner in line for CEO’s job; Vertex wins expanded label for Kalydeco

→ Israel’s Teva is reportedly taking a hard look at a foreigner for its next CEO, sparking a patriotic row.

→ The FDA has approved Vertex’s Kalydeco for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As a result, the Boston biotech bumped up its revenue projections for the year to $770 million.

Cinfa Biotech says its second trial for a biosimilar of Amgen’s Neulasta was positive, hitting primary and secondary endpoints.


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy




EvaluatePharma World Preview 2017